Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Investor Presentation (2016)
25 slides from Recce Pharmaceuticals's investor presentation, 2016

Slide 1: Our Mission: To target the global health problem of superbugs
Our Mission: “To target the global health problem of superbugs” “One of the greatest threats of human health today” World Health Organisation ASX: RCE 1

Slide 2: Disclaimer
Disclaimer ALL CURRENCY AMOUNTS ARE IN AUD UNLESS STATED OTHERWISE. DISCLAIMER This presentation has been prepared by Recce Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You

Slide 3: Business Overview
Business Overview Why is RECCE® 327 important? • Continued use of commercial antibiotics has led to antibiotic-resistant bacteria – superbugs, a major world health issue • RECCE® 327 kills superbugs (G+ & G- bacteria) – and keeps-on killing them • RECCE® 327 is wholly synthetic • RECCE® 327 has show

Slide 4: Corporate Overview
Corporate Overview Shares Market Capitalisation Cash & Deposits Enterprise Value (ASX: RCE) (@$0.27/share) (30 June 2016) 72.64M $19.61M $3.59M $16.02M 4

Slide 5: Corporate Overview
Corporate Overview Validated patents in UK, Germany, France, Italy, Safety test shows no Spain, Sweden signs of toxicity 15/01/16 25/05/16 * r Rapid scale-up of RECCE® 327 manufacture achieved Recce Antibiotics kills, Top IPO Listing Pharma execiitive tb and gonorrhoea for 2016 Bemadette Murdoch 27/

Slide 6: Technology: Very resistant – P. aeruginosa (Gr-ve superbug)
Technology: Very resistant – P. aeruginosa (Gr-ve superbug) Pre-infection Full infection After 1 hour treatment with RECCE® synthetic antibiotic Complete kill 6

Slide 7: RECCE 327 kills at practical speeds
RECCE® 327 kills at practical speeds* Rates of kill of standard bacteria S. aureus E. coli P. aeruginosa S. pyogenes C. difficile 20 – 60 20 – 60 1 – 24 20 – 60 20 – 60 minutes minutes hours minutes minutes Rates of kill of Superbugs S. aureus E. coli P. aeruginosa The same kill-rates for standard b

Slide 8: RECCE 327 does not Fail
RECCE® 327 does not Fail Number of repetitive uses before displaying loss of antibiotic activity S. aureus E. coli P. aeruginosa Commercial Commercial Commercial antibiotic antibiotic antibiotic 8 4 10 RECCE® Antibiotic >25 After repetitive use, the commercial antibiotic loses activity; RECCE® 327 D

Slide 9: Technology – How it works
Technology – How it works RECCE® antibiotics attack protein in the cell wall of bacteria – outward pressure in the bacteria, causes only them to rupture. 9

Slide 10: Natural vs Synthetic
Natural vs Synthetic • Commercial antibiotics are naturally derived – superbugs to them have been forming for millenniums – and will continue to do so • RECCE® 327 is wholly synthetic – superbugs never formed in nature – designed for a purpose! 10

Slide 11: Manufacture
Manufacture 11

Slide 12: Manufacture
Manufacture Highly economical patent-protected process, with key advantages: 1. ‘1 step’ process - Product produced in 1 hour only 2. 100% yield - No raw material losses - No purification steps - No waste disposal 3. Raw material in-expensive & plentiful 4. RECCE® Trademark registered - in global ma

Slide 13: The Board
ece The Board eve 8

Slide 14: Board of Directors
Board of Directors Dr Graham Melrose, BSc(Hons), PhD, MBA, FRACI, CChem, FAICD Executive Chairman • Founder of Recce and inventor of RECCE® antibiotics • Executive Director and Chief Research Executive of Johnson & Johnson (Aust) Pty Ltd in Sydney, with global responsibilities, particularly in Asia-

Slide 15: Board of Directors
Board of Directors James Graham B.Com.(Entrepreneurship), GAICD Executive Director – Responsible for Marketing and Business Development • Founder in the early funding, growth and direction of Recce • Committee-member of W.A. Angel Investors, backers of Australian entrepreneurial companies • Formerly

Slide 16: Board of Directors
Board of Directors Dr Dominic Barnes MBBS, MMedSc, MBA, FAICD Independent Non-Executive Director • Practicing medical doctor and supervisor of over 20 human pharmaceutical trial programs • Directorships and senior regulatory appointments with leading pharmaceutical companies: Shire, AstraZeneca and

Slide 17: Development
Development 17

Slide 18: Intellectual Property
Intellectual Property* Patent Attorneys: Phillips Ormonde Fitzpatrick - Melbourne Patent Family 1 Filed Status Expiry Australia Granted 2028 USA Granted 2029 Europe Granted 2028 Japan Granted 2028 China Granted 2028 Patent Family 2 All PCT Countries Pending 2034 Patent Family 3 Provisional *Manufact

Slide 19: Human Markets ($170B)
Human Markets ($170B) Enormous and Growing Market Potential 1. Antibiotics - around US$40b, estimated to climb 12.5% to US$45b by 2019 1 2. Anti-cancer - around US$100b, estimated to climb 50% to US$150b by 2018 2 3. Anti-viral - around US$30b, estimated to climb 333% to US$100b by 2025 3 1 BCC Rese

Slide 20: RECCE antibiotics: Sepsis
RECCE® antibiotics Sepsis • “Sepsis affects over 26 million people worldwide each year - one third die”* • “It is the largest killer of children and new-born infants in the world” • “Sepsis is increasing at an annual rate of 8-13%” • “In the United States, sepsis kills more people than colon cancer,

Slide 21: RECCE antibiotics
RECCE® antibiotics Three groups of 10 mice were each infected with S.aureus (superbug) • All ten mice treated with RECCE® antibiotic were saved • Nine mice treated with current antibiotic (Oxacillin) survived • Four mice that had no treatment at all, survived. In mice, Efficacy/Safety was achieved i

Slide 22: RECCE anti-virus
RECCE® anti-virus RECCE® 327 vs Influenza, outside of VERO (Monkey) cells Conclusions from Industry standard Plaque- Reduction Neutralization Test Assay (PRNT) using Monkey cells: • RECCE® 327 may be used to target viruses located external to cells - common when the invading virus is located between

Slide 23: RECCE anti-cancer
RECCE® anti-cancer • Equal or better results than Tamoxifen Citrate, commercial antibiotic • RECCE® 327 did not cause toxicity in normal human epithelial cells or Vero (monkey) cells Results from an independent laboratory in USA 23

Slide 24: RECCE – a Technology
RECCE® 327 – a Technology Compared to the risk of a single opportunity from a one-use product - Recce’s technology enjoys the added security of multiple product opportunities. 24

Slide 25: Contact Details
Contact Details Head Office – Sydney Perth Office & Lab Washington Office Level 34, 50 Bridge Street Suite 10, 3 Brodie Hall Drive 1717 Pennsylvania Avenue AMP Centre Technology Park NW SYDNEY NSW 2000 BENTLEY WA 6102 Suite 1025 AUSTRALIA AUSTRALIA WASHINGTON DC 20006 USA Telephone: +61 (2) 8261 076
Source: Internet Archive copy of recce.com.au
More decks from Recce Pharmaceuticals Ltd.
Shareholder Meeting (November 2026)19 slides · Nov 6, 2026
Investor Presentation (November 2026)45 slides · November 2026
Investor Presentation (October 2026)42 slides · October 2026
Shareholder Meeting (September 2026)10 slides · Sep 2, 2026
Investor Presentation (September 2026)42 slides · September 2026
Investor Presentation (August 2026)40 slides · August 2026